CSIMarket
 
Senseonics Holdings Inc   (SENS)
Other Ticker:  
 
 

Senseonics Holdings Inc's Customers Performance

SENS

 
SENS's Source of Revenues During the corresponding time, Senseonics Holdings Inc recorded revenue increase by 11.9 % year on year, sequentially revenue grew by 25.35 %. While revenue at the Senseonics Holdings Inc 's corporate clients

List of SENS Customers




for the same period Senseonics Holdings Inc recorded revenue increase by 11.9 % year on year, sequentially revenue grew by 25.35 %.

List of SENS Customers




Senseonics Holdings Inc's Comment on Sales, Marketing and Customers



We are in the early commercialization stages of Eversense and are focused on driving awareness and adoption of our CGM system amongst intensively managed patients and their healthcare providers.
As described above, we are party to a commercialization agreement with Ascensia, pursuant to which we have granted Ascensia the exclusive right to distribute our 90-day Eversense CGM system and our six-month Eversense CGM system worldwide for use in people with diabetes, with certain exceptions. Pursuant to the Commercialization Agreement, in the United States, Ascensia began providing sales support for the 90-day Eversense product on October 1, 2020 and Ascensia ramped up sales activities and assumed commercial responsibilities for the 90-day Eversense product during the second quarter of 2021. In February 2022, the extended life Eversense E3 CGM system was approved by the FDA and we expect Ascensia to begin commercializing Eversense E3 in the United States in the second quarter of 2022. In anticipation of the launch, we and Ascensia have been designing the go-to-market strategy for the U.S. six-month product.





Senseonics Holdings Inc's Comment on Sales, Marketing and Customers


We are in the early commercialization stages of Eversense and are focused on driving awareness and adoption of our CGM system amongst intensively managed patients and their healthcare providers.
As described above, we are party to a commercialization agreement with Ascensia, pursuant to which we have granted Ascensia the exclusive right to distribute our 90-day Eversense CGM system and our six-month Eversense CGM system worldwide for use in people with diabetes, with certain exceptions. Pursuant to the Commercialization Agreement, in the United States, Ascensia began providing sales support for the 90-day Eversense product on October 1, 2020 and Ascensia ramped up sales activities and assumed commercial responsibilities for the 90-day Eversense product during the second quarter of 2021. In February 2022, the extended life Eversense E3 CGM system was approved by the FDA and we expect Ascensia to begin commercializing Eversense E3 in the United States in the second quarter of 2022. In anticipation of the launch, we and Ascensia have been designing the go-to-market strategy for the U.S. six-month product.








SENS's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Senseonics Holdings Inc 328.22 19.01 -31.64 89
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com